Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.33 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11126902 | 0.79 | CES1 (0.40) | CES1CES2ALDH1A1TP53CA1 | |
| SCHEMBL7116034 | 0.77 | CA1 (0.43) | CES1CES2ALDH1A1TP53CA1 | |
| SCHEMBL29384332 | 0.76 | CES2 (0.44) | CES1CES2PSMB5ALDH1A1TP53 | |
| SCHEMBL5489710 | 0.73 | CA1 (0.50) | CA1LMNAFAAH | |
| SCHEMBL5484425 | 0.73 | CA1 (0.50) | CA1LMNAFAAH | |
| SCHEMBL7269875 | 0.73 | CES1 (0.32) | CES1CES2PSMB5PLA2G2APLA2G5 | |
| SCHEMBL743494 | 0.73 | — | — | |
| SCHEMBL4653044 | 0.70 | ALDH1A1 (0.41) | ALDH1A1MAPK1 | |
| SCHEMBL20500817 | 0.70 | CES2 (0.44) | CES1CES2ALDH1A1LMNAMEN1 | |
| SCHEMBL8949780 | 0.70 | CA1 (0.52) | CES1CES2TP53CA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642614-B2 | Toll-like receptor modulators and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120178774-A1 | TOLL-LIKE RECEPTOR MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-07-12 | — | — | US | disclosed |
| EP-0634450-B1 | Polyether with releasably bound sterically hindered amines as stabilizing agents | CIBA GEIGY AG (CH) | 1999-09-08 | — | — | EP | disclosed |
| EP-0634450-A2 | Polyether with releasably bound sterically hindered amines as stabilizing agents | CIBA-GEIGY AG (CH) | 1995-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178774-A1 | TOLL-LIKE RECEPTOR MODULATORS AND USES THEREOF | TLR4, TLR3, TLR1 | CES1 4171/4885CES2 3069/4885PSMB5 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.